🚀 Medial Secures Investment on Shark Tank India - Fueling the Future of Professional Social Networking. 🔥
Login

News on Medial

Related News

Drug discovery platform Peptris raises Rs 70 Cr in Series A round

EntrackrEntrackr · 1h ago
Drug discovery platform Peptris raises Rs 70 Cr in Series A round
Medial

Drug discovery company Peptris has raised Rs 70 crore ($7.7 million) in a Series A funding round co-led by IAN Alpha Fund and Speciale Invest along with participation from Tenacity Ventures, BYT Ventures, and other investors. The fresh capital will be used to advance its existing programs toward clinical readiness and to expand its pipeline over the next 24 months, and enhance teams across biology, chemistry, data science, and AI, Peptris said in a press release. Co-founded in 2019 by Narayanan Venkatasubramanian, Shridhar Narayanan, Anand Budni, and Amit Mahajan, Peptris has created AI models to generate novel molecules and predict varied parameters that are critical to reduce failures in drug development. The approach has led to the discovery of Novel Chemical Entities (NCE), drug repurposing and rescue opportunities. According to the Bengaluru-based company, it addresses persistent problems in healthcare despite scientific advances, drug discovery remains slow, expensive, and failure-prone, leaving large unmet medical needs. This challenge is most acute in the pre-clinical stage, where time, capital, and scientific uncertainty often derail promising programs much before drugs reach the clinical stage. Peptris says that its platform not only generates novel molecules but also helps predict critical drug development parameters early. This enables faster and better-informed decision-making and has already resulted in the discovery of Novel Chemical Entities (NCEs) as well as drug repurposing and rescue opportunities, with multiple programs now advancing towards clinical development. The company plans to initiate several new NCE programs, alongside multiple drug repurposing and rescue programs (shelved clinical stage drugs of other companies). It follows a B2B engagement model, working closely with pharma, biotech, and select FMCG partners to license assets and co-develop programs. The startup focuses on therapeutic areas including rare diseases, inflammation, oncology, and women’s health to deliver a durable impact for patients, caregivers, and healthcare systems globally.

EndureAir raises $2.85 Mn led by IAN Alpha Fund

EntrackrEntrackr · 5m ago
EndureAir raises $2.85 Mn led by IAN Alpha Fund
Medial

EndureAir raises $2.85 Mn led by IAN Alpha Fund EndureAir Systems, a deep-tech UAV (Unmanned Aerial Vehicle) and aerial robotics firm, has raised Rs 25 crore (about $2.85 million) in funding led by IAN Alpha Fund, with participation from IAN Angel Fund. The proceeds will be used to strengthen its UAV capabilities for the defense ecosystem, expand into enterprise markets, and accelerate the development of next-generation high-altitude logistics and aerial robotics platforms. Founded in 2018 by Dr. Abhishek along with his former students Rama Krishna and Chirag Jain, EndureAir designs and manufactures rugged, indigenous UAVs for logistics, defense, surveillance, and disaster response. Unlike drone assemblers, the brand develops both hardware and software fully in-house, leveraging over 15 years of rotorcraft research and backed by 8 patents in flight dynamics and autonomy. EndureAir’s UAV portfolio includes: Sabal, a heavy-lift logistics drone family (10–70 kg payloads) already inducted by the Indian Army’s Eastern Command; Vibhram, a long-endurance UAV that powered Telangana’s Medicine from the Sky vaccine delivery program; and Alakh, a nano-UAV series deployed in critical rescue missions from Chamoli cloudburst to the Turkey earthquake. It is also co-developing high-altitude logistics drones with Bharat Electronics Limited (BEL) and piloting missions in Bhutan with Druk Holding & Investments (DHI). The Noida-based startup competes with players like IdeaForge, Garuda Aerospace, and NewSpace Research.

e-TRNL Energy raises Rs 27.4 Cr seed round led by IAN Group

EntrackrEntrackr · 5d ago
e-TRNL Energy raises Rs 27.4 Cr seed round led by IAN Group
Medial

e-TRNL Energy raises Rs 27.4 Cr seed round led by IAN Group Battery cell technology startup e-TRNL Energy has raised Rs 27.4 crore (around $3 million) in a seed funding round led by IAN Group through its IAN Alpha Fund. The round also saw participation from Navam Capital, Speciale Invest, and other investors. The proceeds will be used to complete product development, validate performance and safety, and demonstrate manufacturing capability in India. Founded in 2021 by Apoorv Shaligram and Dr. Uttam Kumar Sen, e-TRNL Energy is developing next-generation battery cell technology focused on redesigning core cell architecture and manufacturing processes. The startup has established a 20,000 sq. ft. R&D and early manufacturing facility in Bengaluru. It has been granted two patents and has filed additional patent applications. e-TRNL plans to set up a 250 MWh pilot manufacturing facility by 2027, with plans to scale to 2 GWh capacity later. Its first product will use LFP (Lithium Iron Phosphate) chemistry, with future development planned for LMFP and sodium-ion batteries.

Lamark Biotech raises Rs 6.5 Cr in pre-Series A round led by IAN Group

EntrackrEntrackr · 7m ago
Lamark Biotech raises Rs 6.5 Cr in pre-Series A round led by IAN Group
Medial

Lamark Biotech raises Rs 6.5 Cr in pre-Series A round led by IAN Group Lamark's proprietary ProteoStrong platform enables the stabilization of fragile protein-based drugs, such as insulin, monoclonal antibodies, and enzymes, without altering their molecular structure. Biopharma startup Lamark Biotech has raised Rs 6.5 crore in a pre-Series A round led by IAN Group, including IAN Alpha Fund, powered by BioAngels, Vinayender Tulla, Nita Roy, and Venkataraman KNK. Domain experts from IAN’s angel investors led the round. The Ahmedabad-based company had previously raised $41.3K in a seed funding round led by VIT-TBI and others. The fresh funds will be utilized to accelerate the development of thermostable insulin and expand the biologics platform for global access, Lamark said in a press release. Founded in 2018 by Vaibhav Bhatia, Lamark Biotech aims to reimagine drug delivery for chronic and life-altering diseases. Its proprietary ProteoStrong platform enables the stabilization of fragile protein-based drugs, such as insulin, monoclonal antibodies, and enzymes, without altering their molecular structure. According to Lamark Biotech, it leverages the R&D base of Venture Center, NCL Innovation, and it is advancing a new class of temperature-resilient biologics that retain potency across extreme conditions—ideal for underserved regions where cold storage infrastructure is limited. With its lead program, InsulinStrong, Lamark is targeting the Rs 4,000 crore Indian insulin market and intends to expand across Southeast Asia and the UAE. In the next 24 months, it plans to file new international patents, begin early clinical trials, and build partnerships with pharma companies, CDMOs, and global health agencies.

IAN Group marks final close of $100 Mn Alpha Fund

EntrackrEntrackr · 2m ago
IAN Group marks final close of $100 Mn Alpha Fund
Medial

IAN Group marks final close of $100 Mn Alpha Fund Early-stage investment platform IAN Group has completed the final close of its second venture capital vehicle, the IAN Alpha Fund, with a corpus of $100 million. The fund aims to back early-stage, tech-enabled startups addressing major industry and societal challenges. Its investment focus spans sectors such as artificial intelligence, space tech, semiconductors, climate, healthcare, and other frontier domains. The Alpha Fund saw backing from a mix of institutional and government-linked investors, including funds like the Self-Reliant India Fund, SIDBI Fund of Funds for Startups, ACE Fund, and Odisha Startup Growth Fund, along with insurance and family-office investors. According to IAN, several of its initial portfolio companies, 10 to 12 so far, are led by first-generation founders based in tier-II and tier-III cities. IAN enables entrepreneurs to raise from Rs 50 lakhs to Rs 50 crore on a single platform, along with mentoring and global market access. The Group’s investment thesis has been to invest in startups in emerging sectors led by exceptional founders solving real problems or building for India’s strategic imperatives, while giving exceptional investor returns. Over the last 19 years, it claims to have consistently returned capital with multiples in high double digits. The fund follows IAN’s broader vision of supporting startup growth across geographies and sectors, with a stated aim to help founders in smaller cities get the same opportunities as those in major urban centres. In August this year, IAN Group had also appointed Chintan Thakkar as Group CEO of IAN Group.

Download the medial app to read full posts, comements and news.